|NASDAQ: ZYXI||Healthcare / Medical Devices & Instruments / USA|
|10.99||+0.3200||+3.00%||Vol 149.46K||1Y Perf 67.77%|
|Mar 24th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||19.83||Analyst Rating||Strong Buy 1.00|
|Potential %||80.44||Finscreener Ranking||★★★★+ 55.82|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★+ 48.54|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★★★★★ 74.03|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||46.31||Earnings Rating||—|
|Market Cap||402.61M||Earnings Date||-|
Today's Price Range
5 Year PE Ratio Range
|10 Years||3 629.22%|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||227.71K|
|Avg. Monthly Volume||315.99K|
|Avg. Quarterly Volume||278.49K|
Zynex Inc. (NASDAQ: ZYXI) stock closed at 10.99 per share at the end of the most recent trading day (a 3% change compared to the prior day closing price) with a volume of 149.46K shares and market capitalization of 402.61M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 768 people. Zynex Inc. CEO is Thomas Sandgaard.
The one-year performance of Zynex Inc. stock is 67.77%, while year-to-date (YTD) performance is -20.99%. ZYXI stock has a five-year performance of 203.74%. Its 52-week range is between 5.59 and 17.25, which gives ZYXI stock a 52-week price range ratio of 46.31%
Zynex Inc. currently has a PE ratio of 33.30, a price-to-book (PB) ratio of 9.24, a price-to-sale (PS) ratio of 5.51, a price to cashflow ratio of 37.50, a PEG ratio of 2.32, a ROA of 17.94%, a ROC of 21.17% and a ROE of 28.76%. The company’s profit margin is 8.77%, its EBITDA margin is 18.20%, and its revenue ttm is $109.36 Million , which makes it $2.84 revenue per share.
Of the last four earnings reports from Zynex Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Zynex Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Zynex Inc. is Strong Buy (1), with a target price of $19.83, which is +80.44% compared to the current price. The earnings rating for Zynex Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Zynex Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Zynex Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 14.63, ATR14 : 0.66, CCI20 : -21.21, Chaikin Money Flow : -0.10, MACD : -0.57, Money Flow Index : 35.00, ROC : 13.77, RSI : 43.75, STOCH (14,3) : 80.10, STOCH RSI : 1.00, UO : 42.34, Williams %R : -19.90), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Zynex Inc. in the last 12-months were: Anna Lucsok (Sold 1 103 shares of value $15 420 ), Daniel J. Moorhead (Sold 38 126 shares of value $407 186 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Moderate Buy|
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave, Non-Invasive Blood Volume Monitor and others.
CEO: Thomas Sandgaard
Telephone: +1 303 703-4906
Address: 9555 Maroon Circle, Englewood 80112, CO, US
Number of employees: 768
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.